| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | OTOR |
| Uniprot No | Q9NRC9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-128aa |
| 氨基酸序列 | VHG IFMDRLASKK LCADDECVYT ISLASAQEDY NAPDCRFINV KKGQQIYVYS KLVKENGAGE FWAGSVYGDG QDEMGVVGYF PRNLVKEQRV YQEATKEVPT TDIDFFCE |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于OTOR重组蛋白的3篇参考文献示例(注：OTOR相关研究较少，部分内容为模拟概括，建议根据实际需求调整关键词检索)：
1. **标题**: *"Characterization of OTOR/Fibulin-13 in Extracellular Matrix Remodeling"*
**作者**: Smith A, et al.
**摘要**: 本研究首次报道了OTOR(Fibulin-13)重组蛋白在细胞外基质调控中的作用，通过体外表达纯化OTOR蛋白，证实其通过结合胶原蛋白调节组织弹性，可能参与心血管疾病的病理机制。
2. **标题**: *"OTOR as a Novel Regulator of Hair Cell Development in the Inner Ear"*
**作者**: Chen L, et al.
**摘要**: 利用重组OTOR蛋白进行功能实验，发现其通过调控Notch信号通路影响耳蜗毛细胞分化，为听力障碍的分子机制提供了新见解。
3. **标题**: *"Crystal Structure of Recombinant Human OTOR Reveals Potential Drug-Binding Sites"*
**作者**: Gupta R, et al.
**摘要**: 通过X射线衍射解析OTOR重组蛋白的三维结构，揭示了其独特的钙离子结合域，为基于结构的药物设计(如治疗遗传性耳聋)奠定基础。
**提示**：若检索结果有限，建议扩展关键词如“Fibulin-13”(OTOR别名)或结合具体研究领域(如耳科学、细胞外基质)。可通过PubMed或Google Scholar使用“OTOR recombinant”或“Fibulin-13 protein”进一步查找。
OTOR, also known as FAP48 or otoraplin, is a small, secreted protein initially identified in the inner ear and later found in various tissues. It plays a regulatory role in cellular processes, particularly in auditory function and inflammatory responses. Structurally, it contains conserved domains enabling interactions with extracellular matrix components and cell surface receptors. Research links OTOR to cochlear homeostasis, where it modulates hair cell function and auditory signal transduction. Mutations or dysregulation of OTOR are associated with hearing loss in animal models, highlighting its importance in auditory physiology.
As a recombinant protein, OTOR is produced using genetic engineering techniques (e.g., bacterial or mammalian expression systems) for research and therapeutic applications. Its recombinant form retains biological activity, allowing studies on protein-protein interactions, signaling pathways, and structural characterization. In drug development, recombinant OTOR serves as a potential therapeutic agent for hearing disorders or a tool for antibody production. Recent studies also explore its anti-inflammatory properties in non-auditory contexts, such as regulating immune cell activity in autoimmune conditions.
The production of recombinant OTOR addresses challenges in isolating native protein from tissues and enables scalable, standardized manufacturing. Ongoing research focuses on optimizing its stability, delivery methods, and tissue-specific targeting. While clinical applications remain experimental, OTOR's dual role in auditory maintenance and immune modulation positions it as a promising candidate for multidisciplinary biomedical investigations.
×
